Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk

Results from the BONE study

P. D. Delmas, Robert R. Recker, C. H. Chesnut, A. Skag, J. A. Stakkestad, R. Emkey, J. Gilbride, R. C. Schimmer, C. Christiansen

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of bone turnover is therefore becoming a more widely used endpoint in clinical trials in postmenopausal osteoporosis. This multinational double-blind, fracture-prevention study enrolled 2946 postmenopausal women with osteoporosis. Patients were randomized to receive placebo or oral ibandronate administered daily (2.5 mg/day) or intermittently (20 mg every other day for 12 doses every 3 months). The primary endpoint was the incidence of new vertebral fractures after 3 years. Secondary outcome measures included changes in the rate of bone turnover as assessed by biochemical markers and increases in spinal and hip BMD. Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62% and 50%, respectively, and produced significant and sustained reductions in all the measured biochemical markers of bone turnover. By 3 months, the rate of bone turnover was reduced by approximately 50-60%, and this level of suppression was sustained throughout the remainder of the study. In summary, oral ibandronate, given daily or with a between-dose interval of > 2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures. Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)792-798
Number of pages7
JournalOsteoporosis International
Volume15
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Bone Remodeling
Bone Density
Postmenopausal Osteoporosis
Biomarkers
Pelvic Bones
Incidence
Diphosphonates
Osteoporosis
ibandronic acid
Placebos
Outcome Assessment (Health Care)
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk : Results from the BONE study. / Delmas, P. D.; Recker, Robert R.; Chesnut, C. H.; Skag, A.; Stakkestad, J. A.; Emkey, R.; Gilbride, J.; Schimmer, R. C.; Christiansen, C.

In: Osteoporosis International, Vol. 15, No. 10, 10.2004, p. 792-798.

Research output: Contribution to journalArticle

Delmas, P. D. ; Recker, Robert R. ; Chesnut, C. H. ; Skag, A. ; Stakkestad, J. A. ; Emkey, R. ; Gilbride, J. ; Schimmer, R. C. ; Christiansen, C. / Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk : Results from the BONE study. In: Osteoporosis International. 2004 ; Vol. 15, No. 10. pp. 792-798.
@article{8b8f1304a2424a80bfe61644455f6174,
title = "Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study",
abstract = "Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of bone turnover is therefore becoming a more widely used endpoint in clinical trials in postmenopausal osteoporosis. This multinational double-blind, fracture-prevention study enrolled 2946 postmenopausal women with osteoporosis. Patients were randomized to receive placebo or oral ibandronate administered daily (2.5 mg/day) or intermittently (20 mg every other day for 12 doses every 3 months). The primary endpoint was the incidence of new vertebral fractures after 3 years. Secondary outcome measures included changes in the rate of bone turnover as assessed by biochemical markers and increases in spinal and hip BMD. Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62{\%} and 50{\%}, respectively, and produced significant and sustained reductions in all the measured biochemical markers of bone turnover. By 3 months, the rate of bone turnover was reduced by approximately 50-60{\%}, and this level of suppression was sustained throughout the remainder of the study. In summary, oral ibandronate, given daily or with a between-dose interval of > 2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures. Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis.",
author = "Delmas, {P. D.} and Recker, {Robert R.} and Chesnut, {C. H.} and A. Skag and Stakkestad, {J. A.} and R. Emkey and J. Gilbride and Schimmer, {R. C.} and C. Christiansen",
year = "2004",
month = "10",
doi = "10.1007/s00198-004-1602-9",
language = "English",
volume = "15",
pages = "792--798",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "10",

}

TY - JOUR

T1 - Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk

T2 - Results from the BONE study

AU - Delmas, P. D.

AU - Recker, Robert R.

AU - Chesnut, C. H.

AU - Skag, A.

AU - Stakkestad, J. A.

AU - Emkey, R.

AU - Gilbride, J.

AU - Schimmer, R. C.

AU - Christiansen, C.

PY - 2004/10

Y1 - 2004/10

N2 - Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of bone turnover is therefore becoming a more widely used endpoint in clinical trials in postmenopausal osteoporosis. This multinational double-blind, fracture-prevention study enrolled 2946 postmenopausal women with osteoporosis. Patients were randomized to receive placebo or oral ibandronate administered daily (2.5 mg/day) or intermittently (20 mg every other day for 12 doses every 3 months). The primary endpoint was the incidence of new vertebral fractures after 3 years. Secondary outcome measures included changes in the rate of bone turnover as assessed by biochemical markers and increases in spinal and hip BMD. Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62% and 50%, respectively, and produced significant and sustained reductions in all the measured biochemical markers of bone turnover. By 3 months, the rate of bone turnover was reduced by approximately 50-60%, and this level of suppression was sustained throughout the remainder of the study. In summary, oral ibandronate, given daily or with a between-dose interval of > 2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures. Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis.

AB - Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of bone turnover is therefore becoming a more widely used endpoint in clinical trials in postmenopausal osteoporosis. This multinational double-blind, fracture-prevention study enrolled 2946 postmenopausal women with osteoporosis. Patients were randomized to receive placebo or oral ibandronate administered daily (2.5 mg/day) or intermittently (20 mg every other day for 12 doses every 3 months). The primary endpoint was the incidence of new vertebral fractures after 3 years. Secondary outcome measures included changes in the rate of bone turnover as assessed by biochemical markers and increases in spinal and hip BMD. Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62% and 50%, respectively, and produced significant and sustained reductions in all the measured biochemical markers of bone turnover. By 3 months, the rate of bone turnover was reduced by approximately 50-60%, and this level of suppression was sustained throughout the remainder of the study. In summary, oral ibandronate, given daily or with a between-dose interval of > 2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures. Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=4344580653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344580653&partnerID=8YFLogxK

U2 - 10.1007/s00198-004-1602-9

DO - 10.1007/s00198-004-1602-9

M3 - Article

VL - 15

SP - 792

EP - 798

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 10

ER -